Compare MUX & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MUX | COLL |
|---|---|---|
| Founded | 1979 | 2002 |
| Country | Canada | United States |
| Employees | 1432 | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | N/A | 2015 |
| Metric | MUX | COLL |
|---|---|---|
| Price | $26.02 | $39.74 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | $23.38 | ★ $50.83 |
| AVG Volume (30 Days) | ★ 877.6K | 323.9K |
| Earning Date | 01-01-0001 | 05-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.73 |
| Revenue | N/A | ★ $780,567,000.00 |
| Revenue This Year | $3.01 | $5.70 |
| Revenue Next Year | $45.01 | N/A |
| P/E Ratio | ★ N/A | $23.07 |
| Revenue Growth | N/A | ★ 23.62 |
| 52 Week Low | $6.38 | $23.23 |
| 52 Week High | $29.70 | $50.79 |
| Indicator | MUX | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 50.56 | 26.17 |
| Support Level | $22.96 | $34.30 |
| Resistance Level | $27.33 | $39.85 |
| Average True Range (ATR) | 1.49 | 1.54 |
| MACD | -0.14 | -0.63 |
| Stochastic Oscillator | 50.17 | 5.35 |
McEwen Inc, formerly McEwen Mining Inc is a mining and minerals production and exploration company that focuses on precious and base minerals in Argentina, Mexico, and the United States. The company generates its revenue from gold and silver production. It owns and operates the wholly-owned El Gallo 1 mine in Mexico and holds a minority stake in the company that manages the San Jose mine in Argentina. More than half of the company's gold output comes from the El Gallo 1 mine, while the remaining gold production and the majority of silver production are sourced from the San Jose mine. Geographically, majority of production occurs in the United States.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.